Get the Stockscreener App
5.245
1.06%
0.055
Puma Biotechnology Inc stock is traded at $5.245, with a volume of 376.25K.
It is up +1.06% in the last 24 hours and up +7.04% over the past month.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
See More
Previous Close:
$5.19
Open:
$5.16
24h Volume:
376.25K
Relative Volume:
0.71
Market Cap:
$264.30M
Revenue:
$230.47M
Net Income/Loss:
$30.28M
P/E Ratio:
8.5984
EPS:
0.61
Net Cash Flow:
$38.86M
1W Performance:
+3.86%
1M Performance:
+7.04%
6M Performance:
+47.33%
1Y Performance:
+65.98%
1-Day Range:
$5.16
$5.315
1-Week Range:
$4.835
$5.315
52-Week Range:
$2.575
$6.12
Puma Biotechnology Inc Stock (PBYI) Company Profile
Name
Puma Biotechnology Inc
Sector
Industry
Phone
(424) 248-6500
Address
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
5.245 | 261.53M | 230.47M | 30.28M | 38.86M | 0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Underperform |
| Oct-08-19 | Downgrade | Goldman | Neutral → Sell |
| May-10-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-10-19 | Downgrade | Citigroup | Buy → Neutral |
| Jan-17-19 | Initiated | Leerink Partners | Mkt Perform |
| Jan-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-19-18 | Upgrade | Goldman | Sell → Neutral |
| Nov-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Nov-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-18 | Initiated | Goldman | Sell |
| May-11-18 | Reiterated | Stifel | Buy |
| Nov-10-17 | Reiterated | Citigroup | Buy |
| Nov-10-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-02-17 | Reiterated | Stifel | Buy |
| Sep-11-17 | Reiterated | Credit Suisse | Outperform |
| Jul-10-17 | Resumed | Leerink Partners | Outperform |
| Jun-06-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-25-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Mar-02-17 | Reiterated | RBC Capital Mkts | Sector Perform |
View All
Puma Biotechnology Inc Stock (PBYI) Latest News
What insider trading reveals about Puma Biotechnology Inc. stock2025 Top Gainers & Daily Oversold Bounce Ideas - Newser
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - PharmiWeb.com
With 60% ownership of the shares, Puma Biotechnology, Inc. (NASDAQ:PBYI) is heavily dominated by institutional owners - Yahoo Finance
Puma Biotechnology, Inc. (PBYI) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
What dividend safety score for Puma Biotechnology Inc. stockPortfolio Growth Summary & Precise Buy Zone Tips - moha.gov.vn
Total debt per share of Puma Biotechnology, Inc. – TRADEGATE:0PB - TradingView
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick? - sharewise.com
Check out these key findings about Puma Biotechnology Inc (PBYI) - Setenews
Will Puma Biotechnology Inc. stock continue upward momentumGDP Growth & AI Forecast Swing Trade Picks - newser.com
Is Puma Biotechnology Inc. stock affected by interest rate hikes2025 Earnings Impact & Real-Time Volume Surge Alerts - newser.com
Using Ichimoku Cloud for Puma Biotechnology Inc. technicalsJuly 2025 Short Interest & Fast Entry and Exit Trade Plans - newser.com
Using data filters to optimize entry into Puma Biotechnology Inc.July 2025 Drop Watch & Intraday High Probability Alerts - newser.com
Published on: 2025-11-19 05:37:08 - newser.com
Using fundamentals and technicals on Puma Biotechnology Inc.Trend Reversal & Stepwise Trade Execution Plans - newser.com
Adversity is less terrifying than hope: Puma Biotechnology Inc (PBYI) - Setenews
1stdibs.Com And 2 Other Penny Stocks To Watch Closely - simplywall.st
Puma Biotechnology, Inc.Corporate Presentation, November 2025 (11/17/2025 10: 08 - MarketScreener
How strong is Puma Biotechnology Inc. stock revenue growthWeekly Trade Review & Capital Protection Trading Alerts - newser.com
Using R and stats models for Puma Biotechnology Inc. forecastingJuly 2025 WrapUp & Real-Time Volume Trigger Notifications - newser.com
Published on: 2025-11-18 22:41:28 - newser.com
Published on: 2025-11-14 15:23:18 - newser.com
Can Puma Biotechnology Inc. stock withstand economic slowdownMarket Activity Summary & Entry Point Strategy Guides - newser.com
Why retail investors favor Puma Biotechnology Inc. stock2025 Growth vs Value & Weekly Breakout Watchlists - Fundação Cultural do Pará
Aug Final Week: Is Puma Biotechnology Inc. stock a safe buy before earnings - Fundação Cultural do Pará
Insider Sell: Michael Miller Sells 20,000 Shares of Puma Biotech - GuruFocus
Puma Biotechnology Director Sells 20,000 Shares - TradingView
[Form 4] PUMA BIOTECHNOLOGY, INC. Insider Trading Activity - Stock Titan
Puma Biotechnology Inc Stock (PBYI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):